Compare SFM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFM | ROIV |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 25.1B |
| IPO Year | 2013 | 2021 |
| Metric | SFM | ROIV |
|---|---|---|
| Price | $73.20 | $41.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $98.89 | $28.94 |
| AVG Volume (30 Days) | 1.6M | ★ 7.9M |
| Earning Date | 04-29-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.60 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $8,806,159,000.00 | $8,260,000.00 |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $7.36 | $744.61 |
| P/E Ratio | $23.74 | ★ N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $64.75 | $13.83 |
| 52 Week High | $139.71 | $42.50 |
| Indicator | SFM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 66.10 |
| Support Level | $64.88 | $33.15 |
| Resistance Level | $80.46 | N/A |
| Average True Range (ATR) | 3.68 | 1.37 |
| MACD | -1.12 | 0.53 |
| Stochastic Oscillator | 1.24 | 78.11 |
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.